Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 163 for your search:
Cancer Type:
Lymphoma, non-Hodgkin lymphoma, child
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
15 to 60
Sponsor:
Other
Protocol IDs:
Hemato INCAN 01/2007
, NCT00429065
3.
Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors
Phase:
Phase IV
Type:
Supportive care, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2006-00055-18
, NCT00415103
4.
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
5.
Trial of Levofloxacin as Prophylaxis After Allogeneic Stem Cell Transplantation (SCT)
Phase:
Phase III, Phase II
Type:
Supportive care, Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
Levosta-CBF-02/04
, NCT00215007
6.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
7.
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
8.
Combination Chemotherapy Plus Steroid Therapy in Treating Children With Acute Lymphoblastic Leukemia or Lymphoblastic Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 18
Sponsor:
Other
Protocol IDs:
EORTC-58951
, NCT00003728
9.
Combination Chemotherapy in Treating Children With Anaplastic Large Cell Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 22
Sponsor:
Other
Protocol IDs:
FRE-IGR-ALCL99
, EU-20031, NHL2000/06, NCT00006455
10.
Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI
Protocol IDs:
FHCRC-1813.00
, 5666, NCT00075478
11.
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients Receiving Vincristine for Wilms' Tumor, Rhabdomyosarcoma, Acute Lymphoblastic Leukemia, or Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
NCI
Protocol IDs:
HLMCC-0402
, NCT00369564, ACCL 0731
12.
Budesonide for Prevention of Acute Gastrointestinal GVHD Following Allogenic Stem Cell Transplantation
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
12 to 65
Sponsor:
Other
Protocol IDs:
PROGAST
, NCT00180089
13.
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
2004-0107
, NCT00500240
14.
Biological Therapy in Treating Patients With Lymphoma or Lymphoproliferative Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
15.
Peripheral Stem Transplantation in Treating Patients With Refractory or Relapsed Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
FHCRC-1409.00
, 4903, NCI-G00-1776, NCT00005803
16.
Chemotherapy Followed by Allogeneic Stem Cell Transplantation in Treating Children With Hematologic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
4 to 21
Sponsor:
NCI
Protocol IDs:
NCI-01-C-0125F
, NCT00020592
17.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
18.
Allogeneic Transplantation From Related Haploidentical Donors in Older Patients With Indolent Hematologic Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Older patients
Sponsor:
NCI, Other
Protocol IDs:
BMT124
, 75117, BMT124, NCT00185692, NCT00185692
19.
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
1 to 21
Sponsor:
NCI
Protocol IDs:
COG-ANHL06P1
, ANHL06P1, NCT00354107
20.
Clofarabine in Treating Patients With T-Cell or Natural Killer-Cell Non-Hodgkin’s Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 and over
Sponsor:
NCI
Protocol IDs:
MSKCC-06065
, NCT00416351
21.
Allogeneic Cytokine-Induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
12 to 60
Sponsor:
Other
Protocol IDs:
CIK#2/2007
, NMRC/1097/2006, NCT00460694
22.
Clofarabine, Melphalan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Diseases
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
75 and under
Sponsor:
NCI
Protocol IDs:
UCCRC-14341B
, 14341B, UCCRC-05-155, NCT00572546
23.
Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
24.
Monoclonal Antibody Therapy, Fludarabine, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
Under 100
Sponsor:
Other
Protocol IDs:
BCM-H-12472
, H 12472, BCM-ACHE, NCT00056966
25.
Vaccine Therapy and Donor Lymphocyte Infusions in Treating Patients With Progressive or Relapsed Hematologic Malignancies After Donor Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
1 to 75
Sponsor:
NCI
Protocol IDs:
NCI-08-C-0051
, 08-C-0051, NCI-P06049, NCT00608166
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute
